OXPHOS-targeting drugs in oncology: new perspectives

References

• Yap TA, Daver N, Mahendra M, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29(1):115–126.
   PubMedGoogle Scholar
• Zhang X, Dang CV. Time to hit pause on mitochondria-targeting cancer therapies. Nat Med. 2023;29(1):29–30.
   PubMedGoogle Scholar
• Ashton TM, McKenna WG, Kunz-Schughart LA, et al. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018 Jun 1;24(11):2482–2490. doi: 10.1158/1078-0432.CCR-17-3070
   PubMed Web of Science ®Google Scholar
• Xu Y, Xue D, Bankhead A 3rd, et al. Why all the Fuss about oxidative phosphorylation (OXPHOS)? J Med Chem. 2020 Dec 10;63(23):14276–14307. doi: 10.1021/acs.jmedchem.0c01013
   PubMed Web of Science ®Google Scholar
• Huang M, Myers CR, Wang Y, et al. Mitochondria as a novel target for cancer chemoprevention: emergence of mitochondrial-targeting agents. Cancer Prev Res (Phila). 2021 Mar;14(3):285–306. doi: 10.1158/1940-6207.CAPR-20-0425
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B. Teaching the basics of repurposing mitochondria-targeted drugs: from Parkinson’s disease to cancer and back to Parkinson’s disease. Redox Biol. 2020 Aug 3;36:101665. doi: 10.1016/j.redox.2020.101665
   PubMed Web of Science ®Google Scholar
• Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015 Sep 15;43(3):435–449. doi: 10.1016/j.immuni.2015.09.001
   PubMed Web of Science ®Google Scholar
• Smith RAJ, Porteous CM, Gane AM, et al. Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5407–5412. doi: 10.1073/pnas.0931245100
   PubMed Web of Science ®Google Scholar
• Murphy MP, Hartley RC. Mitochondria as a therapeutic target for common pathologies. Nat Rev Drug Discov. 2018 Dec;17(12):865–886. doi: 10.1038/nrd.2018.174
   PubMed Web of Science ®Google Scholar
• Ashton TM, Fokas E, Kunz-Schughart LA, et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nat Commun. 2016 Jul 25;7(1):12308. doi: 10.1038/ncomms12308
   PubMedGoogle Scholar
• Benej M, Hong X, Vibhute S, et al. Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10756–10761. doi: 10.1073/pnas.1808945115
   PubMed Web of Science ®Google Scholar
• Nishida M, Yamashita N, Ogawa T, et al. Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes. J Immunother Cancer. 2021 Sep;9(9):e002954. doi: 10.1136/jitc-2021-002954
   PubMed Web of Science ®Google Scholar
• Chandran K, Aggarwal D, Migrino RQ, et al. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J. 2009 Feb 18;96(4):1388–1398. doi: 10.1016/j.bpj.2008.10.042
   PubMed Web of Science ®Google Scholar
• Graham D, Huynh NN, Hamilton CA, et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009 Aug;54(2):322–328. doi: 10.1161/HYPERTENSIONAHA.109.130351
   PubMed Web of Science ®Google Scholar
• Capeloa T, Krzystyniak J, d’Hose D, et al. MitoQ inhibits human breast cancer cell migration, invasion and Clonogenicity. Cancers (Basel). 2022 Mar 16;14(6):1516. doi: 10.3390/cancers14061516
   PubMed Web of Science ®Google Scholar
• Capeloa T, Van de Velde JA, d’Hose D, et al. Inhibition of mitochondrial redox signaling with MitoQ prevents metastasis of human pancreatic cancer in mice. Cancers (Basel). 2022 Oct 7;14(19):4918. doi: 10.3390/cancers14194918
   PubMed Web of Science ®Google Scholar
• Capeloa T, Krzystyniak J, Rodriguez AC, et al. MitoQ prevents human breast cancer recurrence and lung metastasis in mice. Cancers (Basel). 2022 Mar 15;14(6):1488. doi: 10.3390/cancers14061488
   PubMed Web of Science ®Google Scholar
• Yoon NG, Lee H, Kim SY, et al. Mitoquinone inactivates mitochondrial chaperone TRAP1 by blocking the client binding site. J Am Chem Soc. 2021 Dec 1;143(47):19684–19696. doi: 10.1021/jacs.1c07099
   PubMed Web of Science ®Google Scholar
• Yoshida S, Tsutsumi S, Muhlebach G, et al. Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):E1604–12. doi: 10.1073/pnas.1220659110
   PubMed Web of Science ®Google Scholar
• Rasola A, Neckers L, Picard D. Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells. Trends Cell Biol. 2014 Aug;24(8):455–463. doi: 10.1016/j.tcb.2014.03.005
   PubMed Web of Science ®Google Scholar
• Cheng G, Karoui H, Hardy M, et al. Redox-crippled MitoQ potently inhibits breast cancer and glioma cell proliferation: a negative control for verifying the antioxidant mechanism of MitoQ in cancer and other oxidative pathologies. Free Radic Biol Med. 2023 Aug 20;205:175–187. doi: 10.1016/j.freeradbiomed.2023.06.009
   PubMed Web of Science ®Google Scholar
• Smith RAJ, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ [conference paper]. Ann N Y Acad Sci. 2010;1201:96–103.
   PubMed Web of Science ®Google Scholar
• Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA. 2010 May 11;107(19):8788–8793. doi: 10.1073/pnas.1003428107
   PubMed Web of Science ®Google Scholar
• Fink B, Coppey L, Davidson E, et al. Effect of mitoquinone (Mito-Q) on neuropathic endpoints in an obese and type 2 diabetic rat model. Free Radic Res. 2020 May;54(5):311–318. doi: 10.1080/10715762.2020.1754409
   PubMed Web of Science ®Google Scholar
• Gottwald EM, Duss M, Bugarski M, et al. The targeted anti-oxidant MitoQ causes mitochondrial swelling and depolarization in kidney tissue. Physiol Rep. 2018 Apr;6(7):e13667. doi: 10.14814/phy2.13667
   PubMed Web of Science ®Google Scholar
• Pan J, Lee Y, Cheng G, et al. Mitochondria-targeted honokiol confers a striking inhibitory effect on lung cancer via inhibiting complex I activity. iScience. 2018 May 25;3:192–207. doi: 10.1016/j.isci.2018.04.013
   PubMed Web of Science ®Google Scholar
• Cheng G, Hardy M, Zielonka J, et al. Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells. Cancer Treat Res Commun. 2020 Sep 17;25:100210.
   PubMedGoogle Scholar
• AbuEid M, McAllister DM, McOlash L, et al. Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression. iScience. 2021 Jun 25;24(6):102653. doi: 10.1016/j.isci.2021.102653
   PubMed Web of Science ®Google Scholar
• Huang M, Xiong D, Pan J, et al. Prevention of tumor growth and dissemination by in situ vaccination with Mitochondria-Targeted Atovaquone. Adv Sci. 2022;9(12):2101267. doi: 10.1002/advs.202101267
   Web of Science ®Google Scholar
• Cheng G, Hardy M, Topchyan P, et al. Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone Sci Rep. 2020 Oct 21;10(1):17872. doi: 10.1038/s41598-020-74808-0
   Google Scholar
• Cheng G, Zhang Q, Pan J, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019;10(1):2205. doi: 10.1038/s41467-019-10042-1
   PubMedGoogle Scholar
• Fischer GM, Jalali A, Kircher DA, et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov. 2019 May;9(5):628–645. doi: 10.1158/2159-8290.CD-18-1489
   PubMed Web of Science ®Google Scholar
• Janku F, Beom SH, Moon YW, et al. First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2022 Oct;40(5):1001–1010. doi: 10.1007/s10637-022-01277-9
   PubMed Web of Science ®Google Scholar
• Izreig S, Gariepy A, Kaymak I, et al. Repression of LKB1 by miR-17∼92 sensitizes MYC-Dependent lymphoma to biguanide treatment. Cell Rep Med. 2020 May 19;1(2):100014. doi: 10.1016/j.xcrm.2020.100014
   PubMedGoogle Scholar
• Cheng G, Zielonka J, Ouari O, et al. Mitochondria-targeted analogues of metformin exhibit enhanced antiproliferative and radiosensitizing effects in pancreatic cancer cells. Cancer Res. 2016 Jul 1;76(13):3904–3915. doi: 10.1158/0008-5472.CAN-15-2534
   PubMed Web of Science ®Google Scholar
• Boyle KA, Van Wickle J, Hill RB, et al. Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation. J Biol Chem. 2018 Sep 21;293(38):14891–14904. doi: 10.1074/jbc.RA117.001469
   PubMed Web of Science ®Google Scholar
• AbuEid M, Keyes RF, McAllister D, et al. Fluorinated triphenylphosphonium analogs improve cell selectivity and in vivo detection of mito-metformin. iScience. 2022 Dec 22;25(12):105670. doi: 10.1016/j.isci.2022.105670
   PubMed Web of Science ®Google Scholar
• Cheng G, Hardy M, Topchyan P, et al. Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects. iScience. iScience. 2021 Jun 25;24(6):102673. doi: 10.1016/j.isci.2021.102673
   PubMed Web of Science ®Google Scholar
• Bielcikova Z, Stursa J, Krizova L, et al. Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial. EClinicalMedicine. 2023 Mar;57:101873. doi: 10.1016/j.eclinm.2023.101873
   PubMedGoogle Scholar
• Rohlenova K, Sachaphibulkij K, Stursa J, et al. Selective disruption of respiratory supercomplexes as a new strategy to suppress Her2(high) breast cancer. Antioxid Redox Signal. 2017 Jan 10;26(2):84–103. doi: 10.1089/ars.2016.6677
   PubMed Web of Science ®Google Scholar
• Reddy CA, Somepalli V, Golakoti T, et al. Mitochondrial-targeted curcuminoids: a strategy to enhance bioavailability and anticancer efficacy of curcumin. PLoS One. 2014;9(3):e89351. doi: 10.1371/journal.pone.0089351
   PubMed Web of Science ®Google Scholar
• Jayakumar S, Patwardhan RS, Pal D, et al. Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity. Free Radic Biol Med. 2017 Dec;113:530–538.
   PubMed Web of Science ®Google Scholar
• Mattarei A, Romio M, Managò A, et al. Novel mitochondria-targeted furocoumarin derivatives as possible anti-cancer agents. Front Oncol. 2018;8:122. doi: 10.3389/fonc.2018.00122
   PubMed Web of Science ®Google Scholar
• Pathak RK, Marrache S, Harn DA, et al. Mito-DCA: a mitochondria targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate [article]. ACS Chem Biol. 2014 May 16;9(5):1178–1187. doi: 10.1021/cb400944y
   PubMed Web of Science ®Google Scholar
• Kolb D, Kolishetti N, Surnar B, et al. Metabolic modulation of the tumor microenvironment leads to multiple checkpoint inhibition and immune cell infiltration. ACS Nano. 2020;14(9):11055–11066. doi: 10.1021/acsnano.9b10037
   PubMed Web of Science ®Google Scholar
• Molina JR, Sun Y, Protopopova M, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018 Jul;24(7):1036–1046. doi: 10.1038/s41591-018-0052-4
   PubMed Web of Science ®Google Scholar
• Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem. 1997 Feb 14;272(7):3961–3966. doi: 10.1074/jbc.272.7.3961
   PubMed Web of Science ®Google Scholar
• Radloff PD, Philipps J, Nkeyi M, et al. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet. 1996 Jun 1;347(9014):1511–1514. doi: 10.1016/S0140-6736(96)90671-6
   PubMed Web of Science ®Google Scholar
• Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993 May 27;328(21):1521–1527. doi: 10.1056/NEJM199305273282103
   PubMed Web of Science ®Google Scholar
• Freeman CD, Klutman NE, Lamp KC, et al. Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother. 1998 Oct;32(10):1004–1007. doi: 10.1345/aph.17464
   PubMed Web of Science ®Google Scholar
• Darade A, Pathak S, Sharma S, et al. Atovaquone oral bioavailability enhancement using electrospraying technology. Eur J Pharm Sci. 2018 Jan 1;111:195–204. doi: 10.1016/j.ejps.2017.09.051
   PubMed Web of Science ®Google Scholar
• Dixon R, Pozniak AL, Watt HM, et al. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother. 1996 Mar;40(3):556–560. doi: 10.1128/AAC.40.3.556
   PubMed Web of Science ®Google Scholar
• Nixon GL, Moss DM, Shone AE, et al. Antimalarial pharmacology and therapeutics of atovaquone. J Antimicrob Chemother. 2013;68(5):977–985. doi: 10.1093/jac/dks504
   PubMed Web of Science ®Google Scholar
• Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4’-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol. 1992 Apr 1;43(7):1545–1553. doi: 10.1016/0006-2952(92)90213-3
   PubMed Web of Science ®Google Scholar
• Mather MW, Darrouzet E, Valkova-Valchanova M, et al. Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. J Biol Chem. 2005 Jul 22;280(29):27458–27465. doi: 10.1074/jbc.M502319200
   PubMed Web of Science ®Google Scholar
• Fiorillo M, Lamb R, Tanowitz HB, et al. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget. 2016 Jun 7;7(23):34084–34099. doi: 10.18632/oncotarget.9122
   PubMedGoogle Scholar
• Xiang M, Kim H, Ho VT, et al. Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016 Oct 6;128(14):1845–1853. doi: 10.1182/blood-2015-07-660506
   PubMed Web of Science ®Google Scholar
• Gupta N, Srivastava SK. Atovaquone: an antiprotozoal drug suppresses primary and resistant breast tumor growth by inhibiting HER2/β-catenin signaling. Mol Cancer Ther. 2019 Oct;18(10):1708–1720. doi: 10.1158/1535-7163.MCT-18-1286
   PubMed Web of Science ®Google Scholar
• Tian S, Chen H, Tan W. Targeting mitochondrial respiration as a therapeutic strategy for cervical cancer. Biochem Biophys Res Commun. 2018 May 23;499(4):1019–1024. doi: 10.1016/j.bbrc.2018.04.042
   PubMed Web of Science ®Google Scholar
• Loftus RM, Finlay DK. Immunometabolism: cellular metabolism turns immune regulator. J Biol Chem. 2016 Jan 1;291(1):1–10. doi: 10.1074/jbc.R115.693903
   PubMed Web of Science ®Google Scholar
• Andrejeva G, Rathmell JC. Similarities and distinctions of cancer and immune metabolism in inflammation and tumors. Cell Metab. 2017 Jul 5;26(1):49–70. doi: 10.1016/j.cmet.2017.06.004
   PubMed Web of Science ®Google Scholar
• Li X, Wenes M, Romero P, et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019 Jul;16(7):425–441. doi: 10.1038/s41571-019-0203-7
   PubMed Web of Science ®Google Scholar
• Gaber T, Strehl C, Buttgereit F. Metabolic regulation of inflammation. Nat Rev Rheumatol. 2017 May;13(5):267–279. doi: 10.1038/nrrheum.2017.37
   PubMed Web of Science ®Google Scholar
• Tasdogan A, Ubellacker JM, Morrison SJ. Redox regulation in cancer cells during metastasis. Cancer Discov. 2021 Nov;11(11):2682–2692. doi: 10.1158/2159-8290.CD-21-0558
   PubMed Web of Science ®Google Scholar
• Tasdogan A, Faubert B, Ramesh V, et al. Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature. 2020 Jan;577(7788):115–120. doi: 10.1038/s41586-019-1847-2
   PubMed Web of Science ®Google Scholar
• Burton LP, Deng G, Yanes CD, et al. Novel metformin analogues for treatment of pancreatic cancer. J Endocr Soc. 2021;5:1027–1028. doi: 10.1210/jendso/bvab048.2103
   Google Scholar
• Lord SR, Harris AL. Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? Br J Cancer. 2023 Apr;128(6):958–966. doi: 10.1038/s41416-023-02204-2
   PubMed Web of Science ®Google Scholar
• McGuinness ME, Talbert RL. Phenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann Pharmacother. 1993 Oct;27(10):1183–1187. doi: 10.1177/106002809302701004
   PubMed Web of Science ®Google Scholar
• Zhao H, Swanson KD, Zheng B. Therapeutic repurposing of biguanides in cancer. Trends Cancer. 2021 Aug;7(8):714–730. doi: 10.1016/j.trecan.2021.03.001
   PubMed Web of Science ®Google Scholar
• Di Magno L, Manni S, Di Pastena F, et al. Phenformin inhibits hedgehog-dependent tumor growth through a complex I-Independent redox/corepressor module. Cell Rep. 2020 Feb 11;30(6):1735–1752.e7. doi: 10.1016/j.celrep.2020.01.024
   PubMed Web of Science ®Google Scholar
• Veiga SR, Ge X, Mercer CA, et al. Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR. Clin Cancer Res. 2018 Aug 1;24(15):3767–3780. doi: 10.1158/1078-0432.CCR-18-0177
   PubMed Web of Science ®Google Scholar
• Masoud R, Reyes-Castellanos G, Lac S, et al. Targeting mitochondrial complex I overcomes chemoresistance in high OXPHOS pancreatic cancer. Cell Rep Med. 2020 Nov 17;1(8):100143. doi: 10.1016/j.xcrm.2020.100143
   PubMedGoogle Scholar
• Hollinshead KER, Parker SJ, Eapen VV, et al. Respiratory supercomplexes promote mitochondrial efficiency and growth in severely hypoxic pancreatic cancer. Cell Rep. 2020 Oct 6;33(1):108231. doi: 10.1016/j.celrep.2020.108231
   PubMed Web of Science ®Google Scholar
• Stemberkova-Hubackova S, Zobalova R, Dubisova M, et al. Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy. Clin Transl Med. 2022 Mar;12(3):e645. doi: 10.1002/ctm2.645
   PubMed Web of Science ®Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19. N Engl J Med. 2020 Aug 6;383(6):517–525. doi: 10.1056/NEJMoa2016638
   PubMed Web of Science ®Google Scholar
• Crunkhorn S. Targeting the mitochondria to block tumour growth. Nat Rev Drug Discov. 2021 Feb;20(2):97. doi: 10.1038/d41573-021-00001-1
   PubMed Web of Science ®Google Scholar
• Zorova LD, Popkov VA, Plotnikov EY, et al. Mitochondrial membrane potential. Anal Biochem. 2018 Jul 1;552:50–59. doi: 10.1016/j.ab.2017.07.009
   PubMed Web of Science ®Google Scholar
• Zielonka J, Joseph J, Sikora A, et al. Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev. 2017 Jun 27;117(15):10043–10120. doi: 10.1021/acs.chemrev.7b00042
   PubMed Web of Science ®Google Scholar
• Dong L, Neuzil J. Targeting mitochondria as an anticancer strategy. Cancer Commun. 2019 Oct 25;39(1):1–3. doi: 10.1186/s40880-019-0412-6
   Web of Science ®Google Scholar
• Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020 Apr 10;368(6487). doi: 10.1126/science.aaw5473
   PubMed Web of Science ®Google Scholar
• Gouirand V, Guillaumond F, Vasseur S. Influence of the tumor microenvironment on cancer cells metabolic reprogramming. Front Oncol. 2018;8:117. doi: 10.3389/fonc.2018.00117
   PubMed Web of Science ®Google Scholar
• Cheng G, Zielonka J, McAllister D, et al. Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. Br J Cancer. 2014 Jul 8;111(1):85–93. doi: 10.1038/bjc.2014.272
   PubMed Web of Science ®Google Scholar
• LeBleu VS, O’Connell JT, Gonzalez Herrera KN, et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014 Oct;16(10):992-1003, 1–15. doi: 10.1038/ncb3039
   Web of Science ®Google Scholar
• Park JH, Vithayathil S, Kumar S, et al. Fatty acid oxidation-driven src links mitochondrial energy reprogramming and oncogenic properties in triple-negative breast cancer. Cell Rep. 2016 Mar 8;14(9):2154–2165. doi: 10.1016/j.celrep.2016.02.004
   PubMed Web of Science ®Google Scholar
• Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, et al. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the “reverse Warburg effect” in positive lymph node tissue. Cell Cycle. 2012 Apr 1;11(7):1445–1454. doi: 10.4161/cc.19841
   PubMed Web of Science ®Google Scholar
• Bartman CR, Weilandt DR, Shen Y, et al. Slow TCA flux and ATP production in primary solid tumours but not metastases. Nature. 2023 Feb;614(7947):349–357. doi: 10.1038/s41586-022-05661-6
   PubMed Web of Science ®Google Scholar
• Najjar YG, Menk AV, Sander C, et al. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019 Mar 7;4(5). doi: 10.1172/jci.insight.124989
   PubMed Web of Science ®Google Scholar
• Jaiswal AR, Liu AJ, Pudakalakatti S, et al. Melanoma evolves complete immunotherapy resistance through the acquisition of a hypermetabolic phenotype. Cancer Immunol Res. 2020 Nov;8(11):1365–1380. doi: 10.1158/2326-6066.CIR-19-0005
   PubMed Web of Science ®Google Scholar
• McManus MJ, Murphy MP, Franklin JL. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2011 Nov 2;31(44):15703–15715. doi: 10.1523/JNEUROSCI.0552-11.2011
   PubMed Web of Science ®Google Scholar
• Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629–656.
   PubMed Web of Science ®Google Scholar
• d’Hose D, Mathieu B, Mignion L, et al. EPR investigations to study the impact of Mito-metformin on the mitochondrial function of prostate cancer cells. Molecules. 2022 Sep 10;27(18). doi: 10.3390/molecules27185872
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B, Cheng G, Hardy M, et al. Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms. Interface Focus. 2017 Apr 6;7(2):20160109. doi: 10.1098/rsfs.2016.0109
   PubMed Web of Science ®Google Scholar
• Skwarski M, McGowan DR, Belcher E, et al. Mitochondrial inhibitor atovaquone increases tumor oxygenation and inhibits hypoxic gene expression in patients with non-small cell lung cancer. Clin Cancer Res. 2021 May 1;27(9):2459–2469. doi: 10.1158/1078-0432.CCR-20-4128
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B, Cheng G, Zielonka J, et al. Low-temperature EPR spectroscopy as a probe-Free technique for monitoring oxidants formed in tumor cells and tissues: implications in drug resistance and OXPHOS-Targeted therapies. Cell Biochem Biophys. 2019 Mar;77(1):89–98. doi: 10.1007/s12013-018-0858-1
   PubMed Web of Science ®Google Scholar
• Cheng G, Zielonka M, Dranka B, et al. Detection of mitochondria-generated reactive oxygen species in cells using multiple probes and methods: potentials, pitfalls, and the future. J Biol Chem. 2018 Jun 29;293(26):10363–10380. doi: 10.1074/jbc.RA118.003044
   PubMed Web of Science ®Google Scholar
• Bridges HR, Fedor JG, Blaza JN, et al. Structure of inhibitor-bound mammalian complex I. Nat Commun. 2020 Oct 16;11(1):5261. doi: 10.1038/s41467-020-18950-3
   PubMed Web of Science ®Google Scholar
• Naguib A, Mathew G, Reczek CR, et al. Mitochondrial complex I inhibitors expose a vulnerability for selective killing of Pten-null cells. Cell Rep. 2018 Apr 3;23(1):58–67. doi: 10.1016/j.celrep.2018.03.032
   PubMed Web of Science ®Google Scholar
• Weinberg SE, Singer BD, Steinert EM, et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature. 2019 Jan;565(7740):495–499. doi: 10.1038/s41586-018-0846-z
   PubMed Web of Science ®Google Scholar
• Zhao Z, Mei Y, Wang Z, et al. The effect of oxidative phosphorylation on cancer drug resistance. Cancers (Basel). 2022 Dec 22;15(1):62. doi: 10.3390/cancers15010062
   PubMed Web of Science ®Google Scholar
• Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab. 2020 Sep 1;32(3):341–352. doi: 10.1016/j.cmet.2020.06.019
   PubMed Web of Science ®Google Scholar
• De Francesco EM, Ózsvári B, Sotgia F, et al. Dodecyl-TPP targets mitochondria and potently eradicates Cancer Stem Cells (CSCs): synergy with FDA-Approved drugs and natural compounds (vitamin C and berberine). Front Oncol. 2019;9:615. doi: 10.3389/fonc.2019.00615
   PubMed Web of Science ®Google Scholar